SynthesisInternational journal of clinical pharmacy2023
The safety and efficacy of gabapentinoids in the management of neuropathic pain: a systematic review with meta-analysis of randomised controlled trials.
Synthesis in International journal of clinical pharmacy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 6 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Use of pregabalin and limaprost in the conservative treatment of lumbar spinal stenosis: a systematic review of the current evidence.European journal of clinical pharmacology · 2026Pooled it
- Skeletal muscle relaxant for the treatment of fibromyalgia: a systematic review and meta-analysis of randomized controlled trials.Regional anesthesia and pain medicine · 2025Pooled it
- Effectiveness of gabapentinoids in orthopedic surgeries: a systematic review and meta-analysis of postoperative pain, and opioid-sparing effects.BMC anesthesiology · 2025Pooled it
- Multimorbidity and analgesic-related harms: a systematic review.British journal of anaesthesia · 2025Pooled it
- Pooled it
- Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials.International journal of molecular sciences · 2023Pooled it
- Long-term efficacy of 10 kHz spinal cord stimulation in managing painful diabetic neuropathy: A post-study survey.Pain practice : the official journal of World Institute of Pain · 2025Trial
- Effect of an experimental pregabalin gel on dental sensitivity and color change after bleaching with 35% hydrogen peroxide: a randomized clinical trial.Clinical oral investigations · 2025Trial
- How the Reclassification of Gabapentinoids Reshaped Neuropathic Pain Treatment in Saudi Arabia: A Survey of Healthcare Professionals.Pain and therapy · 2026Article
- Gabapentinoids-duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting.British journal of clinical pharmacology · 2026Review
- Gabapentin Utilization and Adverse Effects Among US Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain.Kidney medicine · 2026Article
- Glaucine suppresses IL-16/CD4 to alleviate neuropathic pain via spinal p56Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Temporal trends in gabapentinoid use for the acute management of spinal cord injury: a retrospective cohort study.Spinal cord · 2026Article
- Production and evaluation of a novel GABA-producing almond yogurt: dietary modulation of stress.Frontiers in veterinary science · 2026Article
- Gabapentin CNS exposure and analgesic response are modulated by OCT2 genotype in patients with chronic neuropathic pain.Frontiers in pharmacology · 2026Article
- Itching, Ionic Channels, Immune System, Magnesium and Antioxidants.Clinical, cosmetic and investigational dermatology · 2026Review
- Calcium Channel αPain and therapy · 2025Review
- Efficacy of gabapentin and pregabalin for the treatment of neurogenic claudication in lumbar spinal stenosis: a double-blind randomized placebo-controlled trial.Asian spine journal · 2025Article
- Hydrogel-Based Delivery Systems for Non-Opioid Analgesics: Advances, Challenges, and Clinical Prospects.Journal of clinical medicine · 2025Review
- A cross-sectional study of prescribing of antiseizure medication for the treatment of pain in Australia.International journal of clinical pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere are increasing concerns regarding the abusive potential of gabapentinoids putting at risk patients with neuropathic pain requiring long-term pain management. The evidence to support this is rather inconcusive.
aimThis systematic review aimed to evaluate the safety and efficacy of gabapentinoids in the management of neuropathic pain with a focus on randomised controlled trials (RCTs) and categorising the side effects according to the body systems they were affecting.
methodSearches were conducted in MEDLINE (PubMed), EMBASE, Web of Science, PsycoINFO, and CINAHL (EBSCO), and included RCTs to identify and critically appraise studies investigating safety and therapeutic effects of gabapentionoids in adults with neuropathic pain. Data extraction was conducted using an established Cochrane form and the risk-of-bias tool was used in the assessment of quality.
results50 studies (12,398 participants) were included. The majority of adverse events pertained to the nervous system (7 effects) or psychiatric (3 effects) disorders. There were more adverse effects reported with pregabalin (36 effects) than with gabapentin (22 effects). Six pregabalin studies reported euphoria as a side effect, while no studies reported euphoria with gabapentin. This was the only side effect that may correlate with addictive potential. Gabapentioids were reported to significantly reduce pain compared to placebo.
conclusionDespite RCTs documenting the adverse events of gabapentionoids on the nervous system, there was no evidence of gabapentinoid use leading to addiction, suggesting an urgent need to design studies investigating their abusive potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.